Drug Profile

Research programme: p38 MAP kinase inhibitors - Bristol-Myers Squibb

Alternative Names: BMS-480188; BMS-487418; BMS-626531; BMS-640994

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Class Amides; Thiazoles
Mechanism of Action P38 mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Inflammation

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
08 Sep 2010 Preclinical development is ongoing in USA
20 Aug 2009 Pharmacodynamics and pharmacokinetics data from preclinical trials in Inflammation presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com